"These findings suggest that administering a booster dose at around 6 to 7 months following the initial immunization will likely enhance protection against SARS-CoV-2 and its variants." Experimental Merck pill halves hospitalizations, deaths Merck & Co's experimental oral antiviral drug for COVID-19, molnupiravir, reduced by around 50% the chance of hospitalization or death for patients with mild or moderate infections who had risk factors for severe disease, according to interim clinical trial results announced by the company https://bit.ly/3zVtyE5 on Friday.
The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.
"The presence of these anti-spike antibodies in the cord blood should, at least in theory, offer these newborns some degree of protection," a researcher said.
Recomiendan vacuna de covid-19 para madres lactantes y embarazadas dallasnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dallasnews.com Daily Mail and Mail on Sunday newspapers.
Doctors are warning of an uptick of severe cases among pregnant women a group with a low vaccination rate that has also been found to be subject to a high risk for complications related to the virus.